ClinicalTrials.gg
CompletedNCT02396316VEGAUpdated Sep 15, 2017Results posted

Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients

A Phase 3 interventional study of Aflibercept (Eylea, BAY 86-5321) and Sham Injection in Glaucoma, Neovascular, sponsored by Bayer. Completed at 19 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-09-15.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.

02

Conditions studied

  • Glaucoma, Neovascular

Browse trials for

03

In context

Glaucoma, Neovascular

39 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.

This study's enrollment of 54 is above the median of 40 across 32 interventional studies indexed under Glaucoma, Neovascular.

Browse Glaucoma, Neovascular studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese men and women aged 20 years or older,
  • Patients diagnosed as having Neovascular glaucoma (NVG) with neovascularization in the anterior segment (both iris and anterior chamber angle),
  • Patients with Intraocular pressure (IOP) higher than 25 mmHg in the study eye due to anterior segment (both iris and anterior chamber angle) neovascularization.

Exclusion criteria

Exclusion Criteria:

  • Patients with angle-closure due to conditions other than Neovascular glaucoma
  • Patients with a known or suspected ocular or peri-ocular infection,
  • Patients with severe intraocular inflammation in the study eye,
  • Women who are pregnant, suspected of being pregnant or lactating,
  • Patients with known allergy to aflibercept.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Aflibercept

    Aflibercept 2 mg Intravitreal (IVT) injection group

    Drug: Aflibercept (Eylea, BAY 86-5321)

  • Sham comparator
    Sham Injection

    Sham injection group

    Drug: Sham Injection

Interventions

  • After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.

  • DrugSham Injection

    After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.

06

What researchers measure

Primary outcomes

  1. Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1

    It compared the change in IOP from baseline to pre-dose at Week 1 between the aflibercept group vs the sham group.

    Time frame: From baseline to pre-dose at Week 1

Secondary outcomes

  1. Percentage of Subjects Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Pre-dose at Week 1

    NVI were assessed in the study eye using the NVI grading systems (grade 0 to grade 4). A subject who shows the improvement by at least one grade is considered to be improved. Percentage of subjects who had improved NVI grade was reported.

    Time frame: From baseline to pre-dose at Week 1

07

Results

Posted Jul 21, 2017

Participant flow

Study was conducted at nineteen study centers in Japan, between 02 April 2015 (first subject first visit) and 06 Sep 2016 (last subject last visit).

Participant flow — Overall Study
MilestoneAflibercept 2 mg Intravitreal (IVT) Injection GroupSham Injection Group
Started2727
Treated2727
Received sham injection at week 1100
Received afl injection at week 1022
Received active injection at week 544
Received active injection at week 921
Completed2022
Not completed75
Withdrew: Physician decision10
Withdrew: Progressive disease63
Withdrew: Protocol violation01
Withdrew: Treatment unblinded01

Outcome measures

PrimaryChange in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1

It compared the change in IOP from baseline to pre-dose at Week 1 between the aflibercept group vs the sham group.

Time frame:
From baseline to pre-dose at Week 1
Reported as:
Mean · mmHg
Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1
mmHgAflibercept 2 mg Intravitreal (IVT) Injection GroupSham Injection Group
Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1-8.5 ± 8.7-4.9 ± 10.8
Statistical analysis
  • Aflibercept 2 mg Intravitreal (IVT) Injection Group vs Sham Injection Group · ANCOVA · p = 0.0644 · Difference of ls mean change: -4.9 · 95% CI -10.2 to 0.3
SecondaryPercentage of Subjects Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Pre-dose at Week 1

NVI were assessed in the study eye using the NVI grading systems (grade 0 to grade 4). A subject who shows the improvement by at least one grade is considered to be improved. Percentage of subjects who had improved NVI grade was reported.

Time frame:
From baseline to pre-dose at Week 1
Reported as:
Number · Percentage of participants
Percentage of Subjects Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Pre-dose at Week 1
Percentage of participantsAflibercept 2 mg Intravitreal (IVT) Injection GroupSham Injection Group
Percentage of Subjects Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Pre-dose at Week 170.411.5
Statistical analysis
  • Aflibercept 2 mg Intravitreal (IVT) Injection Group vs Sham Injection Group · Mantel Haenszel · Mh adjusted difference: 59.1 · 95% CI 37.0 to 81.2

Adverse events

Collected over Adverse event data were collected after the first dose of study drug and no later than 30 days after the last dose of study drug. AEs from the first dose of study drug until pre-dose at Week 1 were also reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept 2 mg Intravitreal (IVT) Injection Group—3/27 (11.1%)10/27 (37%)
Sham Injection Group—3/27 (11.1%)12/27 (44.4%)
Aflibercept 2 mg IVT Injection Group (Till Pre-dose at Week 1)—0/27 (0%)6/27 (22.2%)
Sham Injection Group (Till Pre-dose at Week 1)—0/27 (0%)7/27 (25.9%)
Most frequent serious events
Most frequent serious events
EventAflibercept 2 mg Intravitreal (IVT) Injection GroupSham Injection GroupAflibercept 2 mg IVT Injection Group (Till Pre-dose at Week 1)Sham Injection Group (Till Pre-dose at Week 1)
Myocardial ischaemiaCardiac disorders0/271/270/270/27
Diabetic retinopathyEye disorders0/271/270/270/27
Retinal artery occlusionEye disorders1/270/270/270/27
Retinal vein occlusionEye disorders1/270/270/270/27
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/270/270/270/27
Eating disorderPsychiatric disorders0/271/270/270/27
Most frequent other events
Most frequent other events
EventAflibercept 2 mg Intravitreal (IVT) Injection GroupSham Injection GroupAflibercept 2 mg IVT Injection Group (Till Pre-dose at Week 1)Sham Injection Group (Till Pre-dose at Week 1)
Eye painEye disorders0/274/270/271/27
Punctate keratitisEye disorders2/273/272/271/27
Procedural painInjury, poisoning and procedural complications3/270/270/270/27
Conjunctival haemorrhageEye disorders2/271/272/270/27
HyphaemaEye disorders0/272/270/272/27
ConstipationGastrointestinal disorders1/272/270/270/27
DiarrhoeaGastrointestinal disorders2/270/271/270/27
Injection site painGeneral disorders2/271/272/271/27
Intraocular pressure increasedInvestigations0/272/270/271/27
HeadacheNervous system disorders1/272/270/272/27

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aflibercept 2 mg Intravitreal (IVT) Injection GroupSham Injection GroupTotal
Mean68.1 ± 12.766.2 ± 13.767.1 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept 2 mg Intravitreal (IVT) Injection GroupSham Injection GroupTotal
Female549
Male222345
08

Study locations

19 sites
  • Yoshida, Fukui 910-1193, Japan
  • Amagasaki, Hyogo 660-8550, Japan
  • Himeji, Hyogo 671-1227, Japan
  • Kobe, Hyogo 650-0017, Japan
  • Kanazawa, Ishikawa 920-8641, Japan
  • Kawasaki, Kanagawa 216-8511, Japan
  • Sendai, Miyagi 980-8574, Japan
  • Yufu, Oita 879-5593, Japan
  • Hirakata, Osaka 573-1191, Japan
  • Suita, Osaka 565-0871, Japan
  • Takatsuki, Osaka 569-8686, Japan
  • Izumo, Shimane 693-8501, Japan
  • Bunkyo-ku, Tokyo 113-8655, Japan
  • Mitaka, Tokyo 181-8611, Japan
  • Ube, Yamaguchi 755-8505, Japan
  • Chuo, Yamanashi 409-3898, Japan
  • Gifu, 501-1194, Japan
  • Kyoto, 602-0841, Japan
  • Osaka, 545-8586, Japan
09

References and documents

Publications

  • Inatani M, Higashide T, Matsushita K, Miki A, Ueki M, Iwamoto Y, Kobayashi M, Leal S; VEGA Investigators. Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial. Adv Ther. 2021 Feb;38(2):1116-1129. doi: 10.1007/s12325-020-01579-5. Epub 2020 Dec 16. PubMed 33330958 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Jun 2016, 14 months.

Results were first posted in Jul 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2015
First posted
Mar 24, 2015
StartActual
Apr 2, 2015
Primary completionActual
Jun 16, 2016
CompletionActual
Sep 6, 2016
Results first posted
Jul 21, 2017
Last update
Sep 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02396316
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 24, 2015
Start date
Apr 2, 2015
Primary completion
Jun 16, 2016
Completion
Sep 6, 2016
Results posted
Jul 21, 2017
Last update
Sep 15, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion